
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb's stock outlook appears positive due to its consistent growth across various segments, highlighted by a 13% year-over-year increase in surgical revenues to $231 million and a notable 67% growth in premium intraocular lenses from the enVista Envy launch. Additionally, the company's consumer segment generated $476 million in revenues, reflecting an 8% year-over-year growth that exceeded consensus estimates. Furthermore, Bausch & Lomb’s contact lens market share increased to 10%, marking a 40 basis points rise year-over-year, which positions the company favorably within the vision care industry.
Bears say
Bausch & Lomb faces a negative outlook driven by expectations of flat to low-single digit revenue growth, resulting in reduced operating margin improvement and earnings per share (EPS) projections being lowered to $0.67 for 2025 and $0.93 for 2026. Several operational and competitive risks are noted, including slower revenue growth from its product lines, potential market share loss in contact lenses, and disruptions related to commercial execution, which could hinder profitability further. Additionally, the company contends with challenges such as heightened competition from lower-cost providers, macroeconomic factors like currency fluctuations, and ongoing geopolitical tensions, which could suppress market valuation for an extended period.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares